SAN DIEGO--(BUSINESS WIRE)--Jan. 9, 2006--Santarus, Inc. (Nasdaq:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, today announced that it has received notice from TAP Pharmaceutical Products Inc. (TAP), pursuant to the terms of the sublicense agreement entered into in June 2002, that TAP is exercising its right to terminate the sublicense agreement without cause, effective March 7, 2006, 60 days from the date of notice. Under the terms of the sublicense agreement, Santarus granted TAP the North American rights to develop, manufacture and sell products resulting from the use of the company’s immediate-release proton pump inhibitor (PPI) technology with lansoprazole, a PPI.
